Search results for "Forced Expiratory Volume"

showing 10 items of 163 documents

Spirometric criteria to diagnose airway obstruction in the elderly: fixed ratio vs. lower limit of normal.

2015

COPD is the most common chronic lung disease. It becomes more prevalent with increasing age but remains under-diagnosed in the elderly. A heated debate concerns the most suitable way to diagnose airway obstruction in this age group. Most COPD guidelines recommend to use a FEV1/FVC of 0.70 as threshold to define an obstructive ventilatory defect. While the use of a 0.70 ratio may be simple, it may result in under-diagnosis of airflow obstruction in young people and over-diagnosis in the elderly due to an age-related decline in pulmonary volumes, especially in FEV1. This might lead to unnecessary use of medications and increased risk of adverse effects. A proposed strategy for reducing the mi…

COPD diagnosis spirometry airflow obstruction forced expiratory volume
researchProduct

Non-specific bronchial hyper-responsiveness in children with allergic rhinitis: relationship with the atopic status

2003

An increased prevalence of bronchial hyper-responsiveness (BHR) has been demonstrated in children from a general population, and in non-asthmatic adults with allergic rhinitis. Thus, also children with allergic rhinitis are expected to be at higher risk of BHR. We evaluated the prevalence of BHR in a sample of non-asthmatic children with allergic rhinitis by means of the methacholine (Mch) bronchial challenge, and by monitorizing the airway patency using the daily peak expiratory flow variability (PEFv). Fifty-one children (ranged 6-15 years of age) with allergic rhinitis, ascertained by skin prick test to inhalant allergens, underwent a 14-day peak expiratory flow monitoring, and a Mch bro…

Cross-Sectional StudieHypersensitivity ImmediateMaleRhinitis Allergic PerennialAdolescentRespiratory Function Tests; Peak Expiratory Flow Rate; Airway Resistance; Vital Capacity; Bronchial Provocation Tests; Humans; Predictive Value of Tests; Child; Forced Expiratory Volume; Child Welfare; Cross-Sectional Studies; Rhinitis Allergic Perennial; Immunoglobulin E; Hypersensitivity Immediate; Bronchial Hyperreactivity; Statistics as Topic; Adolescent; Male; Biological Markers; Female; PrevalenceAirway ResistanceVital CapacityStatistics as TopicChild WelfarePeak Expiratory Flow RatePredictive Value of TestImmunoglobulin EBronchial Provocation TestForced Expiratory VolumeBiological MarkerPrevalenceFemaleBronchial HyperreactivityChildRespiratory Function TestHuman
researchProduct

Can the response to Omalizumab be influenced by treatment duration? A real-life study

2017

Objective It is unknown whether Omalizumab effectiveness changes over the course of time. Our retrospective real-life study tried to analyze whether Omalizumab response may be influenced by treatment duration. Methods 340 severe asthmatics treated with Omalizumab for different periods of time were recruited. They were subdivided into 4 groups according to the Omalizumab treatment length: 60 months. Omalizumab treatment results (FEV1, exacerbations, ACT, SABA use, asthma control levels, medications used e and ICS doses) were compared. Results ACT, exacerbations, GINA control levels, ICS doses and SABA use were similar in all groups with different Omalizumab treatment durations. Using a linea…

CyclopropanesMaleSevere asthmaTime FactorsTreatment durationQuinolineEffectivenessOmalizumabOmalizumabAcetatesAdrenal Cortex Hormone0302 clinical medicineAdrenal Cortex HormonesRetrospective StudieForced Expiratory VolumeMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineLead (electronics)Adrenergic beta-AgonistConfoundingEffectiveneReal-lifeResponseAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeEffectiveness; Omalizumab; Real-life; Response; Severe asthma; Treatment duration; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)QuinolinesLinear ModelFemaleHumanmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorSulfidesSettore MED/10 - Malattie Dell'Apparato RespiratorioTreatment duration03 medical and health sciencesInternal medicineHumansAnti-Asthmatic AgentMontelukastRetrospective StudiesAsthmaAcetatebusiness.industryBiochemistry (medical)Retrospective cohort studymedicine.diseaseAsthmaDiscontinuationSurgery030228 respiratory systemLinear ModelsbusinessPulmonary Pharmacology & Therapeutics
researchProduct

Palliative Treatment of Dyspnea With Epidural Methadone in Advanced Emphysema

2005

This study investigated whether epidural methadone perfusion at the thoracic level can mitigate dyspnea in patients with advanced emphysema.Open-label clinical trial without a control group.University hospital.The inclusion criteria were a diagnosis of emphysema, basal dyspnea index (Mahler scale)or = 3, FEV(1)or = 35%, and no indication for pneumoreduction or lung transplantation surgery.An epidural catheter was inserted at the thoracic level connected to a perfusion pump for administering methadone (6 mg/24 h). Assessments were made at baseline, 1 week, and 1 month after catheter insertion.Pulmonary function tests were performed, and determinations were made of arterial blood gas levels, …

Epidural SpaceMalePulmonary and Respiratory Medicinemedicine.medical_specialtyPalliative carePalliative treatmentmedicine.medical_treatmentCritical Care and Intensive Care MedicinePulmonary function testingForced Expiratory VolumemedicineHumansLung transplantationIntensive care medicineCatheter insertionbusiness.industryPalliative CareRespiratory diseaseCarbon Dioxidemedicine.diseaseEpidural spacerespiratory tract diseasesSurgeryOxygenCatheterDyspneaTreatment Outcomemedicine.anatomical_structurePulmonary EmphysemaAnesthesiaQuality of LifeArterial bloodFemaleCardiology and Cardiovascular MedicinebusinessMethadoneMethadonemedicine.drugChest
researchProduct

Heritability of Lung Function: A Twin Study Among Never-Smoking Elderly Women

2011

Most studies on lung function heritability have been conducted in smokers and non-smokers using cross-sectional study design. Smoking patterns may, however, confound the contribution of genetic factors. We investigated heritability of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio longitudinally, excluding the effects of smoking. A sample of never smoking female twins (n = 374), aged 63–76 at baseline, answered health questionnaires and attended spirometry in years 2000 and 2003. Bivariate structural equation modeling, restricted to adequate spirometry performances (baseline n = 339, follow-up n = 252), was used to estimate genetic and environ…

GerontologySpirometryVital capacityVital CapacityEnvironmentheritabilityGenetic correlationCorrelation03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineForced Expiratory VolumemedicineTwins DizygoticHumans030212 general & internal medicineLongitudinal Studiestwin studyGenetics (clinical)030304 developmental biologyAged0303 health sciencesmedicine.diagnostic_testbusiness.industrySmokingObstetrics and Gynecologylung functionTwins Monozygoticrespiratory systemHeritabilityMiddle AgedExplained variationTwin studyrespiratory tract diseasesRespiratory Function TestsSpirometryPediatrics Perinatology and Child HealthFemalebusinesscirculatory and respiratory physiologyDemographyTwin Research and Human Genetics
researchProduct

Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases.

2021

Patients with pre-existing respiratory diseases in the setting of COVID-19 may have a greater risk of severe complications and even death.A retrospective, multicenter, cohort study with 5847 COVID-19 patients admitted to hospitals. Patients were separated in two groups, with/without previous lung disease. Evaluation of factors associated with survival and secondary composite end-point such as ICU admission and respiratory support, were explored.1,271 patients (22%) had a previous lung disease, mostly COPD. All-cause mortality occurred in 376 patients with lung disease (29.5%) and in 819 patients without (17.9%) (Previous lung disease is a risk factor for mortality in patients with COVID-19.…

HOPE-COVID-19 Health Outcome Predictive Evaluation for COVID-19Respiratory diseasesOriginal30-Day mortalityenfermedades respiratoriasACE2 angiotensin converting enzyme IIlaw.invention0302 clinical medicineCQ/HCQ chloroquine/hydroxychloroquinelawCOPDrespiratory diseasesPrognosisICU intensive care unitIntensive care unitSTROBE strengthening the reporting of observational studies in epidemiologypronósticomedicine.anatomical_structureEPOCCohort studyPulmonary and Respiratory Medicinemedicine.medical_specialty30-day mortalityRT-PCR real time reverse transcriptase-polymerase chain reactionSARS-CoV-2 severe acute respiratory syndrome coronavirus 2WHO World Health OrganizationMERS middle east respiratory syndrome03 medical and health sciencesInternal medicinemedicineCOPDCOVID-19 2019 novel coronavirusRisk factorIQR interquartile rangeLungmortalidad a 30 díasbusiness.industryFEV1 forced expiratory volume in one secondCOVID-19Retrospective cohort studymedicine.diseaseHR hazard ratioICS inhaled corticosteroidsCI confidence intervalCoronavirusCOPD chronic obstructive pulmonary disease030228 respiratory systemRespiratory failureILD interstitial lung diseaseMiddle East respiratory syndromeprognosisHFNC high flow nasal cannulabusiness
researchProduct

Biochemical, morphological, and functional aspects of systemic and local vitamin A deficiency in the respiratory tract.

1992

HyperplasiaMucous Membranebusiness.industryVitamin A DeficiencyGeneral NeuroscienceGuinea PigsRespiratory SystemVital CapacityPhysiologymedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyVitamin A deficiencymedicine.anatomical_structureHistory and Philosophy of ScienceReference ValuesForced Expiratory VolumeMedicineAnimalsHumansCiliabusinessVitamin ARespiratory tractAnnals of the New York Academy of Sciences
researchProduct

Near-fatal asthma phenotype in the ENFUMOSA Cohort.

2007

Summary Background Near-fatal asthma (NFA) is characterized by severe asthma attacks usually requiring intensive care unit admission. This phenotype of asthma has been studied mainly in acute conditions. Methods The aim of our study was to compare the clinical, functional and inflammatory characteristics of NFA patients with mild to severe asthmatics in stable conditions. We recruited 155 asthmatic patients from five centres of the European Network for Understanding Mechanisms of Severe Asthma: 67 patients with mild-to-moderate asthma controlled by low/medium doses of inhaled corticosteroids; 64 with severe asthma that, despite treatment with high doses of inhaled corticosteroids, long-acti…

Hypersensitivity ImmediateMaleAllergyVital CapacityAnti-asthmatic AgentSeverity of Illness Indexlaw.inventionCohort StudiesLeukocyte CountlawRisk FactorsForced Expiratory Volumenear-fatal asthmaImmunology and AllergyMedicineAnti-Asthmatic AgentsMiddle AgedIntensive care unitInflammation near-fatal asthma severe asthma sputumPhenotypeFemalemedicine.symptomCohort studyAdultinflammation; near-fatal asthma; severe asthma; sputumsevere asthmamedicine.medical_specialtyPartial PressureImmunologyStatus AsthmaticusDrug Administration ScheduleInternal medicineSeverity of illnessHumansRisk factorGlucocorticoidsAsthmaSkin TestsInflammationbusiness.industrysputummedicine.diseaseAsthmarespiratory tract diseasesOxygeninflammationImmunologySputumPatient Compliancebusiness
researchProduct

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

2020

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored al…

ISAR International Severe Asthma RegistrySHARPPediatricsSevere asthmaSA severe asthmaBiologics Oral corticosteroids Real-life Registr Severe asthmaOmalizumabforced expiratory volume in the 1st secondFood &ampGrading of Recommendations Assessmentchronic rhinosinusitis with nasal polyposisFEV1chemistry.chemical_compound0302 clinical medicineQuality of lifeEMAReal WorldEuropean Medicines AgencyBiologics; Oral corticosteroids; Real-life; Registr; Severe asthmaOral corticosteroidsFDA Food & Drug AdministrationImmunology and Allergy030223 otorhinolaryngologySevere Heterogeneous Asthma Research collaborationmusculoskeletal neural and ocular physiologyReal-lifeCRSwNPOCSsBenralizumabDupilumabCRSwNP chronic rhinosinusitis with nasal polyposisGRADESHARP Severe Heterogeneous Asthma Research collaboration Patient-centredSevere Asthma Network in ItalyFDAmedicine.drugPulmonary and Respiratory Medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyDrug AdministrationGINA Global Initiative for AsthmaRW Real WorldImmunologymacromolecular substancesRWSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologicsInternational Severe Asthma RegistryISAR03 medical and health sciencesSADisease registrySARP Severe Asthma Research ProgramPatient-centredmedicineAsthmabusiness.industrySettore MED/09 - MEDICINA INTERNASANI Severe Asthma Network in ItalySANIBiological productmedicine.diseaseOCSs Oral CorticoSteroidsGINASARPSevere Asthma Research ProgramFEV1 forced expiratory volume in the 1st second030228 respiratory systemchemistrynervous systemRegistrEMA European Medicines AgencyDevelopment and EvaluationSevere asthma Biologics Oral corticosteroids Real-life Registrbusinesslcsh:RC581-607Global Initiative for AsthmaMepolizumabGRADE Grading of Recommendations Assessment Development and Evaluation
researchProduct

The role of small airways in monitoring the response to asthma treatment: what is beyond FEV1?

2009

The definition of asthma has evolved from that of an episodic disease characterized by reversible airways constriction to a chronic inflammatory disease of the airways, with at least partially reversible airway constriction. Increasing evidence supports the notion that small and large airways play a central role in asthma pathophysiology with regard to inflammation, remodeling and symptoms. The contribution of the distal airways to the asthma phenotype carries implications for the delivery of inhaled medications to the appropriate areas of the lung and for the monitoring of the response to asthma treatment. Asthma control is evaluated on the basis of symptoms, lung function and exacerbation…

ImmunologyAnti-Inflammatory AgentsBronchiDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAir trappingAdrenal Cortex HormonesForced Expiratory VolumemedicineHumansImmunology and AllergyRespiratory systemsmall airwayAsthmaLungbusiness.industryRespiratory diseaserespiratory systemasthmamedicine.diseaseRespiratory Function Testsrespiratory tract diseasesTreatment Outcomemedicine.anatomical_structureSpirometryImmunologyBronchoconstrictionmedicine.symptombusinessRespiratory tract
researchProduct